Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT00304291
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:53.165054+00:00
Published At
2020-12-28T00:00:00+00:00
Record Updated At
2020-12-28
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Neuromyelitis Optica", "Myelitis, Transverse", "Demyelinating Autoimmune Diseases, CNS", "Autoimmune Diseases of the Nervous System"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2020-12-28"
protocolSection.identificationModule.nctId
"NCT00304291"
protocolSection.identificationModule.officialTitle
"A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic\u0027s Disease)"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE4"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Neuromyelitis Optica (protocolSection.conditionsModule.conditions)
  • Myelitis, Transverse (protocolSection.conditionsModule.conditions)
  • Demyelinating Autoimmune Diseases, CNS (protocolSection.conditionsModule.conditions)
  • Autoimmune Diseases of the Nervous System (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.